EC Number |
Inhibitors |
Structure |
---|
4.1.2.27 | (1R,2S,3R)-1-(1H,1'H-2,2'-biimidazol-4-yl)butane-1,2,3,4-tetraol |
inhibitory to sphinganine 1-phosphate lyase. 53% decrease in circulating lymphocytes after 30 mg/kg oral dose |
|
4.1.2.27 | (1R,2S,3R)-1-(2-(1-benzyl-1H-1,2,4-triazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol |
inhibitory to sphinganine 1-phosphate lyase. 41% decrease in circulating lymphocytes after 30 mg/kg oral dose |
|
4.1.2.27 | (1R,2S,3R)-1-(2-(thiazol-4-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol |
inhibitory to sphinganine 1-phosphate lyase. 33% decrease in circulating lymphocytes after 30 mg/kg oral dose |
|
4.1.2.27 | (2R,3R)-2-azido-3-hydroxyoctadecyl phosphate |
- |
|
4.1.2.27 | (2R,3R,4E)-2-azido-3-hydroxyoctadec-4-en-1-yl phosphate |
- |
|
4.1.2.27 | (2R,3S)-2-azido-3-hydroxyoctadecyl phosphate |
- |
|
4.1.2.27 | (2R,3S,4E)-2-azido-3-hydroxyoctadec-4-en-1-yl phosphate |
- |
|
4.1.2.27 | (2S,3R)-2-azido-3-hydroxyoctadecyl phosphate |
- |
|
4.1.2.27 | (2S,3R,4E)-2-azido-3-hydroxyoctadec-4-en-1-yl phosphate |
- |
|
4.1.2.27 | (2S,3S)-2-azido-3-hydroxyoctadecyl phosphate |
- |
|